NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker
- 23 April 2020
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 33 (10), 1930-1944
- https://doi.org/10.1038/s41379-020-0542-z
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approachesVirchows Archiv, 2012
- Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal TumorsClinical Cancer Research, 2012
- EWSR1‐POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty‐six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 geneGenes, Chromosomes and Cancer, 2010
- ConsensusClusterPlus: a class discovery tool with confidence assessments and item trackingBioinformatics, 2010
- Recurrent Focal Copy-Number Changes and Loss of Heterozygosity Implicate Two Noncoding RNAs and One Tumor Suppressor Gene at Chromosome 3q13.31 in OsteosarcomaCancer Research, 2010
- The NFATc2 Gene Is Involved in a Novel Cloned Translocation in a Ewing Sarcoma Variant That Couples Its Function in Immunology to OncologyClinical Cancer Research, 2009
- Aggrecan is expressed by embryonic brain glia and regulates astrocyte developmentDevelopmental Biology, 2008
- NFAT proteins: key regulators of T-cell development and functionNature Reviews Immunology, 2005
- Extraskeletal myxoid chondrosarcomas do not show a chondrocytic phenotypeLaboratory Investigation, 2004
- Structure and function of aggrecanCell Research, 2002